Cassava Sciences has been granted a patent for a method of inhibiting phosphorylation of the tau protein and/or a TLR4-mediated immune response. The method involves administering a compound that binds to a pentapeptide of filamin A (FLNA) to cells in need, such as those in the central nervous system. The patent also claims a method of inhibiting insulin resistance by administering a compound of Series C-2, Formula I or a pharmaceutically acceptable salt thereof to insulin receptor-containing cells. The administration should be carried out without the presence of a separate mu opioid receptor agonist or antagonist. GlobalData’s report on Cassava Sciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Cassava Sciences, molecular diagnosis biomarkers was a key innovation area identified from patents. Cassava Sciences's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibiting insulin resistance in insulin receptor-containing cells
A recently granted patent (Publication Number: US11661580B2) discloses a method for inhibiting insulin resistance. The method involves administering a compound of Series C-2, Formula I or a pharmaceutically acceptable salt thereof to insulin receptor-containing cells in need of treatment. Importantly, the administration is carried out without the concurrent use of a mu opioid receptor (MOR) agonist or antagonist.
The compound of Series C-2, Formula I, which is the active ingredient in the method, has a specific structural formula. The patent claims also describe alternative compounds of Series C-2, corresponding to Formula II and Formula III, as potential options for use in the method. Additionally, the claims mention a specific compound with a formula shown below as a potential candidate.
The method can be performed by administering the compound or its salt in the form of a pharmaceutical composition. The composition can be dissolved or dispersed in a pharmaceutically acceptable diluent. The patent claims specify that the pharmaceutical composition can be in either liquid or solid form.
The administration of the compound can be carried out multiple times, and in some embodiments, it is performed daily or multiple times daily. This suggests that the method may require repeated dosing for optimal effectiveness.
In summary, the granted patent discloses a method for inhibiting insulin resistance by administering a compound of Series C-2, Formula I or its salt to insulin receptor-containing cells. The method excludes the concurrent use of a MOR agonist or antagonist. The patent claims also provide alternative compounds and describe the use of pharmaceutical compositions in liquid or solid form. The method may require repeated administration for optimal results.